Peer-Reviewed Publication
Diabetes Technol Ther2026;28(7):639-657.July 1, 2026Journal Article
Clinical Impact of Continuous Glucose Monitoring in Noninsulin Treated Type 2 Diabetes: A Review.
Grazia Aleppo1, Anders L Carlson2, Janet B McGill3, Hamza Alshannaq4,5, Rodolfo Galindo6, Davida Kruger7, Carol J Levy8, Jessica Y Matuoka4, Sabrina Ilham4, Guillermo Umpierrez9, Gregory J Norman4
1Division of Endocrinology, Department of Medicine, Northwestern University Feinberg School of Medicine, Chicago, Illinois, USA.
2International Diabetes Center, HealthPartners, Minneapolis, Minnesota, USA.
3Washington University in St. Louis, St. Louis, Missouri, USA.
4Dexcom Inc., San Diego, California, USA.
5Neurocrine Biosciences, San Diego, California, USA.
6University of Miami Miller School of Medicine, Miami, Florida, USA.
7Division of Endocrinology and Diabetes, Bone and Mineral Disorders, Henry Ford Health System, Detroit, Michigan, USA.
8Division of Endocrinology, Department of Medicine, Mount Sinai Medical Center, New York, New York, USA.
9Department of Medicine, Emory University School of Medicine, Atlanta, Georgia, USA.
Abstract
Continuous glucose monitoring (CGM) technology is becoming increasingly available to people with diabetes using insulin therapy; however, availability for people with type 2 diabetes (T2D) not on insulin remains limited. For people with T2D, there is strong evidence of glycemic benefit with CGM use for those treated with insulin, and CGM is accepted as standard of care. This review explores the im…
Create a free account to keep reading
Free members get 10 full research views every month across publications, clinical trials, FDA clearances, adverse events, and NIH grants. No credit card required.
Want unlimited research access? See Pro plans